PET/CT monitors Crohn's disease, guides management

Article

A Belgian study suggests that FDG-PET/CT should supplement endoscopy for assessing the clinical status of Crohn's disease. Hybrid imaging accurately tracks the frequency and intensity of the condition and may help physicians adjust therapy.

A Belgian study suggests that FDG-PET/CT should supplement endoscopy for assessing the clinical status of Crohn's disease. Hybrid imaging accurately tracks the frequency and intensity of the condition and may help physicians adjust therapy.

Dr. Roland Hustinx, head of nuclear medicine at the University Hospital of Liege, and colleagues prospectively assessed 22 Crohn's disease patients. FDG-PET/CT detected 35 of 48 segments confirmed by endoscopy for a sensitivity rate of 72.9%. Logistic regression analysis revealed that the FDG segment standard uptake value was significantly associated with the lesions (p = 0.0002).

"If the PET/CT is positive, the doctor should confirm the results using endoscopy. If the PET/CT is negative, there would be no need for the endoscopy, given the high negative predictive value of the technique," Hustinx said.

He presented the study at the 2007 SNM meeting.

Recent Videos
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
Related Content
© 2025 MJH Life Sciences

All rights reserved.